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METHODS
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• Pediatric patients < 18 years of age with burn
injuries (group 1) and with oncology conditions
(group 2) who received > 1 dose of amikacin for
the empirical treatment of gram-negative bacterial
infections between Jan 2007 to Dec 2009 and Jan
2006 to Dec 2011 were included.
• Patients with burn injuries received amikacin at
10-20 mg/kg/day as part of early empiric
treatment of presumed burn-related sepsis.
• Oncology patients received 20 mg/kg of amikacin
intravenously for treatment of febrile neutropenia.
• Patients were treated once daily and
concentrations were collected immediately before
and 1 hour after the second dose.
• A population PK model was developed to
describe the observed amikacin concentration
over time in both subpopulations.
• Potential covariates examined included sex, body
weight (WT), age (AGE), height, serum creatinine
(SCR, measured by enzymatic method), C-
reactive protein, and serum albumin levels.
• A binary covariate TYPE was created to denote
the two different patient groups (burn 1, oncology
0).
• NONMEM 7.3 and R packages were used for
model development, evaluation and diagnostic
plotting.
INTRODUCTION
Physiologic changes due to disease status can lead
to highly variable pharmacokinetics (PK) of amikacin
in children. Therefore, considerations should be
given when determining optimal amikacin dose for
patients with specific diseases. Improved
understanding of factors influencing PK can allow for
the optimizing of dosage regimens to reduce
adverse effects.
The aim of the study was to undertake a
comparative pharmacometric analysis of amikacin
use in pediatric patients with burn injuries verses
those with oncology conditions.
CONCLUSION
The results of the current study suggest that besides patient-
specific characteristics (current WT, AGE and CRCL) also
disease-related characteristics should be considered when
dosing amikacin in critically ill pediatric patients, in order to
optimize therapeutic concentration targeting.
RESULTS
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DEMOGRAPHICS
Characteristics Burn (N=72) Onc (N=111) Pooled (N=183)
Age (years) 5 (0.83 – 15) 6.2 (0.8 – 16.4) 5.6 (0.83 – 15.8)
Sex (Male) 49 (68.1%) 62 (55.9%) 111 (60.7%)
Weight (kg) 21 (10.5 – 68.5 ) 20 (8.3 – 63.1) 20 (9.5 – 64.1)
Height (cm) 114 (71.9 – 175.8) 115.5 (67 – 175) 114 (70.5 – 175)
Serum Creatinine (mg/dL) 0.4 (0.2 – 1) 0.32 (0.15 - 0.68) 0.35 (0.17 - 0.8)
Creatinine Clearance 
(mL/min/1.73m2)
170.5 (81.1 – 327.5)
195.4 (127.0 –
338.7) 
190 (105.4 – 336.9)
Table 1. Patient characteristics. Sex distribution is presented as male numbers 
(percentage). Other demographics are presented as median (5th – 95th 
percentiles).
Parameters Descriptions
Base Model Final Model Bootstrap Results
Estimates 95% CI Estimates 95% CI Mean 95% CI
CL (L/h) Clearance 2.63 2.47 - 3.11 2.26 1.93 - 2.59 2.28 1.84 - 2.68
V1 (L) Central volume of distribution 1.62 1.26 - 2.2 6.03 4.99 - 7.07 5.75 4.62 - 7.44
Q (L/h) Distribution clearance 1.29 1.05 - 1.55 0.8 0.46 - 1.14 0.81 0.32 - 1.29
V2 (L) Peripheral volume of distribution 8.36 7.32 - 10.8 4.92 2.76 - 7.08 6.22 0.93 - 8.92
CL-AGE Age influence on CL - - 0.17 0.05 - 0.29 0.16 0.03 - 0.31
CL-CRCL Creatinine clearance on CL - - 0.10 - 0.002 - 0.20 0.23 -0.07 - 0.27
CL-WT Weight influence on CL - - 0.47 0.31 - 0.62 0.50 0.30 - 0.63
V1-AGE Age influence on V1 - - 0.25 0.09 - 0.42 0.25 0.06 - 0.45
V1-WT Weight influence on V1 - - 0.54 0.32 - 0.77 0.58 0.29 - 0.79
V2-AGE Age influence on V2 - - 0.22 0.09 - 0.34 0.29 -0.05 - 0.48
CL-TYPE (L/h) Subpopulation influence on CL - - 0.65 0.40 - 0.90 0.64 0.35 - 0.95
V1-TYPE (L) Subpopulation influence on V1 - - 0.27 0.07 - 0.47 0.31 -0.01 - 0.54
ω2 - CL Variance of CL BSV 0.19 0.14 - 0.25 0.046 0.032 - 0.060 0.074 0.018 - 0.075
ω2 - V1 Variance of V1 BSV - - 0.058 0.022 - 0.094 0.043 0.013 - 0.103
ω2 - Q Variance of Q BSV 0.08 -0.02 - 0.18 - - - -
σ2 Variance of prop residual error 0.11 0.08 - 0.14 0.054 0.036 - 0.072 0.064 0.033 - 0.075
Table 2. Parameter estimates. All continuous covariates (AGE, CRCL, WT) were imposed assuming power relationship. The categorical covariate 
TYPE (0=oncology, 1=burn) was imposed assuming linear relationship. Bootstrap finished with 99% successful rate.
BA
Figure 1. Diagnostic plots. A. base model. B. covariate model. Red line, loess smoothing curve with degree=1, span=2/3. 
Figure 2. VPC plots. Solid line, model predicted median 
concentrations; dashed lines, model predicted 5th and 
95th percentile concentrations.
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